NasdaqCM - Delayed Quote • USD
Atossa Therapeutics, Inc. (ATOS)
At close: 4:00 PM EDT
After hours: 5:42 PM EDT
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Steven C. Quay FCAP, M.D., Ph.D. | Chairman, CEO & President | 1.21M | -- | 1951 |
| Ms. Heather Rees CPA | Senior VP of Finance & Principal Accounting Officer | 520.64k | -- | 1973 |
| Ms. Delly Behen P.H.R. | Senior Vice President of Administration & HR | -- | -- | -- |
| Mr. Eric Van Zanten | Vice President of Investor & Public Relations | -- | -- | -- |
| Dr. Richard Graydon M.D., Ph.D. | Interim Chief Medical Officer | -- | -- | -- |
Atossa Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 12
Description
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
Corporate Governance
Atossa Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Recent Events
- Apr 02, 20248-K/A: Corporate Changes & Voting MattersSee Full Filing
- Apr 01, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Mar 18, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Mar 12, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Nov 13, 20238-K: Corporate Changes & Voting MattersSee Full Filing
Upcoming Events
May 13, 2024 - May 17, 2024
Atossa Therapeutics, Inc. Earnings Call
Related Tickers
SLS SELLAS Life Sciences Group, Inc.
1.4600
-3.95%
JAGX Jaguar Health, Inc.
0.1800
+5.88%
OCGN Ocugen, Inc.
1.2800
+8.47%
CTXR Citius Pharmaceuticals, Inc.
0.6648
-9.25%
CADL Candel Therapeutics, Inc.
6.39
-0.62%
AKBA Akebia Therapeutics, Inc.
1.3400
+0.75%
TNXP Tonix Pharmaceuticals Holding Corp.
0.1685
+5.31%
ICU SeaStar Medical Holding Corporation
0.4402
-8.63%
VERU Veru Inc.
1.2700
+4.96%
EYEN Eyenovia, Inc.
0.6282
-11.68%